{"id":66298,"date":"2021-01-04T22:59:41","date_gmt":"2021-01-04T14:59:41","guid":{"rendered":"https:\/\/www.chinapulse.com\/?p=155726"},"modified":"2021-01-04T22:59:41","modified_gmt":"2021-01-04T14:59:41","slug":"inovio-to-partner-with-chinese-biotech-on-covid-19-vaccine-candidate-in-greater-china-marketwatch","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2021\/01\/04\/inovio-to-partner-with-chinese-biotech-on-covid-19-vaccine-candidate-in-greater-china-marketwatch\/","title":{"rendered":"Inovio to partner with Chinese biotech on COVID-19 vaccine candidate in Greater China  MarketWatch"},"content":{"rendered":"<div class=\"barrons-article-ad-wrapper\">\n<div data-track=\"barrons-article-ad-wrap\" class=\"barrons-article-ad sticky_item\">\n<div class=\"barrons-main-article-ad-target sticky_target body_ad\" aria-hidden=\"true\"><\/div>\n<\/div>\n<\/div>\n<p>Shares of Inovio Pharmaceuticals Inc.<\/p>\n<p> <a data-track-hover=\"QuotePeek\" data-charting-symbol=\"STOCK\/US\/XNAS\/INO\" class=\"qt-chip negative\" href=\"https:\/\/www.chinapulse.com\/investing\/stock\/INO?mod=MW_story_quote\"  rel=\"noopener\">INO,<\/a><\/p>\n<p> -1.67%<\/p>\n<p> were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate. As part of the agreement, the privately held Chinese biotech gains exclusive right to develop, manufacture, and commercialize the still-investigational vaccine in China, Hong Kong, Macao, and Taiwan.&#8230;<\/p>\n<p>This news comes via <a href=\"https:\/\/www.chinapulse.com\/\"  title=\"Best source for Chinese news in English\">ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Inovio Pharmaceuticals Inc.<br \/>\n INO,<br \/>\n -1.67%<br \/>\n were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate. As part of the agre&#8230;<\/p>\n","protected":false},"author":250,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144,213,339,1607,194,365,64,1542],"tags":[7582,3472,10324,2419,7035],"class_list":["post-66298","post","type-post","status-publish","format-standard","hentry","category-china","category-china-news","category-hong-kong","category-manufacturing","category-news-chinese-law","category-suzhou","category-taiwan","category-technology","tag-biotech","tag-chinese","tag-covid-19","tag-macau","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/66298"}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/250"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=66298"}],"version-history":[{"count":2,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/66298\/revisions"}],"predecessor-version":[{"id":66302,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/66298\/revisions\/66302"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=66298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=66298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=66298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}